Centro Médico Teknon
Immunotherapy for lung cancer in Spain costs from $30,000 to $60,000 on average. Final pricing depends on the specific drug used, the number of infusion cycles, and the hospital location. Patients save around 50% compared to the US, where this treatment costs $90,000 on average. Most private medical centers include oncologist consultations, nursing care, and routine laboratory monitoring in their service fees.
Bookimed Expert Insight: Choosing JCI-accredited centers in Barcelona provides access to world-class oncology leaders like Dr. Enriqueta Felip. These top-tier facilities, such as Centro Médico Teknon, combine high volume—handling 23,500 operations annually—with elite credentials. While basic immunotherapy starts at lower price points, the real value in Spain lies in integrated care. Large networks like HM Hospitals offer specialized radiotherapy units that complement immunotherapy for better outcomes.
Why choose Spain for immunotherapy for lung cancer?
Access advanced Immunotherapy for lung cancer solutions in trusted clinics .
| Turkey | Austria | Spain | |
| Immunotherapy for lung cancer | from $18,000 | from $30,000 | from $30,000 |
Day 1 - Arrival
Day 2 - Pre-operation
Day 3 - Immunotherapy
Day 4 - Post-operation
Week 1 - Rehabilitation
Week 2 - Rehabilitation
Please keep in mind that each patient"s journey is unique and can vary. Always follow the specific advice provided by your medical team.
Dr. Vergés is a distinguished ophthalmologist with a PhD from Harvard and multiple national research awards, focusing on advanced eye care.
Leading expert in immunotherapy for lung cancer – Dr. Felip integrates novel immunotherapies into treatment protocols at Hospital Quiron Barcelona.
Dr. Joan Albanell Mestres is a leading oncologist at Hospital HM Nou Delfos in Barcelona. He heads the breast cancer program at HM Delfos. Dr. Albanell Mestres also directs oncology services at Mar Health Park. He conducted oncology research on telomerase in New York. His work is cited more than 9,000 times in medical literature.
Immunotherapy for lung cancer is both available and funded in Spain through the National Health System (SNS). Standard checkpoint inhibitors like pembrolizumab and nivolumab are reimbursed for advanced cases. Access to pioneering mRNA therapeutic vaccines and personalized pharmacogenomic therapies is also available through Spain's extensive clinical trial network.
Bookimed Expert Insight: Spain’s oncology market is uniquely researcher-driven, with 83 clinics frequently participating in global trials. This creates a shortcut for patients seeking therapies not yet fully reimbursed by the public system. Some Barcelona hospitals even offer at-home administration programs for drugs like Keytruda to improve patient comfort.
Patient Consensus: Many patients find success by actively requesting specific biomarker testing like ALK, EGFR, and HER2. Those in advanced stages often prioritize centers that bridge the gap between standard care and ongoing research trials.
Immunotherapy for lung cancer in Spain utilizes immune checkpoint inhibitors like Pembrolizumab (Keytruda) and Nivolumab (Opdivo) to treat non-small cell and small cell lung cancer. These therapies are administered at Joint Commission International-accredited facilities in Madrid and Barcelona under Spanish Society of Medical Oncology guidelines.
Bookimed Expert Insight: Spain ranks among our top 5 destinations for oncology partly due to clinic capacity. In Barcelona, Hospital HM Nou Delfos serves 400,000 patients annually, while Centro Médico Teknon offers specialized oncology care. This high volume, combined with access to leading specialists like Dr. Enriqueta Felip, makes Spain a major hub for neoadjuvant and adjuvant immunotherapy protocols.
Patient Consensus: Patients emphasize the necessity of biomarker testing before starting treatment. The practical reality involves weekly chemotherapy for 3 months followed by maintenance sessions and regular PET scans every quarter.
Spain is a top global destination for lung cancer immunotherapy, featuring JCI-accredited facilities like Hospital Ruber Internacional and Centro Médico Teknon. These centers specialize in PD-1/PD-L1 inhibitors and pharmacogenomic tailoring, often overseen by renowned oncologists like Professor Enriqueta Felip for advanced thoracic malignancies.
Bookimed Expert Insight: While many seek out Madrid for its high clinic density, Barcelona clinics like Hospital HM Nou Delfos serve the highest patient volumes, exceeding 400,000 annually. This high throughput typically correlates with more robust clinical trial access for immunotherapy. Patients should verify if their insurance covers metastatic conditions before booking, as these specialized treatments range from $30,000 to $60,000.
Patient Consensus: Patients emphasize consulting official oncology rankings rather than general forums for these treatments. Many suggest prioritizing major institutions for professional oncology care while confirming financial coverage independently.
Foreign patients can access immunotherapy in Spain by enrolling in clinical trials or via private oncology networks in Madrid and Barcelona. Reputable facilities like Centro Médico Teknon and Hospital Ruber Internacional provide advanced therapies including mRNA lung cancer vaccines and combined immunotherapy-chemotherapy protocols.
Bookimed Expert Insight: Spain ranks highly for oncology due to its massive patient capacity, with Hospital HM Nou Delfos alone serving 400,000 patients annually. While standard immunotherapy typically ranges from $12,000 to $25,000, choosing a high-volume Barcelona clinic often ensures faster access to the latest neoadjuvant protocols not yet available in smaller regional centers.
Patient Consensus: Success in treating metastatic cases often relies on combining immunotherapy with chemotherapy. Patients recommend completing at least 4 infusions locally before traveling to manage potential side effects like heart palpitations.
Spain is a global leader in oncology research, currently hosting over 240 clinical trials for lung cancer immunotherapy. Patients have access to cutting-edge Phase I-III studies, including the pioneering BNT116 cancer vaccine trial and novel drug combinations at JCI-accredited centers in Madrid and Barcelona.
Bookimed Expert Insight: While many countries offer standard immunotherapy, Spain stands out for its early-phase trial infrastructure. Clinics like Hospital Ruber Internacional and Centro Médico Teknon integrate 3-Tesla MRI and advanced diagnostics to precisely monitor trial participants. This technical edge often allows patients to access experimental protocols like BNT116 months before they reach other European markets.
Patient Consensus: Patients value that Spain is one of only seven nations hosting the phase one BNT116 vaccine trial. Many emphasize verifying specific trial eligibility, as doctors strictly require PD-L1 expression testing before enrollment.